● Recruiting

Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

Condition: Allogeneic Hematopoietic Cell Transplant · Graft Versus Host Disease · Sponsor: Shanghai Jiao Tong University School of Medicine

PhasePhase 3

Planned participants316

Who can joinAll sexes, 18 Years to 55 Years

Healthy volunteersNo

About this study

This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin (ATG) as graft versus host disease (GVHD) prophylaxis in patients undergoing allogeneic stem cell transplantation from alternative donor.

This description comes directly from the study's public registry record.

Talk to the study team

Jiong HU · 86-13764313546 · hj10709@rjh.com.cn

Li-ning Wang · 86-21-64370045

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin hsopital

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06705062